Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Cannabis rescheduling explained: the DEA process and where it stands

    Since 28 April 2026, FDA-approved marijuana drugs and marijuana covered by a state medical license are in Schedule III; all other marijuana remains in Schedule I.[1][2] A broader proposal to move all marijuana to Schedule III, first published in May 2024, went to a DEA hearing in June and July 2026 and had no final decision as of late September 2026, when the judge paused the proceedings over a request to add a GAO report to the record.[3][4][5] The judge later admitted the report and took written briefs on it instead of reopening the hearing. What were expected to be the final briefs were filed on 5 November 2026, ahead of his recommendation to the DEA administrator.[6] Rescheduling does not legalize recreational use under federal law.[7][2]

    Editor reviewedStrict sourcingUpdated Explainer21 claims · 90% primaryDrugs, alcohol and addiction, Tech policy, Courts and the law

    This page explains a federal legal process. It is not legal, tax or medical advice, and state cannabis laws differ. Status checked against the Federal Register and law-firm summaries on 7 November 2026.

    For help with cannabis or other substance use, the US SAMHSA National Helpline is free and confidential: 1-800-662-HELP (4357).[8]

    The Controlled Substances Act places drugs in one of five schedules based on medical use, abuse potential and safety or dependence risk.[9] Marijuana was in Schedule I.[3] Since 2022 the federal government has been moving it toward Schedule III, but in two separate steps: a narrow medical rule that took effect in April 2026, and a broader proposal that is still pending.[10][1][5] This page explains the process, what has changed and what has not.

    What the schedules mean

    Under the Controlled Substances Act (CSA), Schedule I drugs have no currently accepted medical use, a high potential for abuse and a lack of accepted safety under medical supervision.[11] Schedule III drugs have a lower abuse potential than Schedules I and II and a currently accepted medical use.[11] Ketamine, anabolic steroids and certain lower-strength codeine products are in Schedule III.[12]

    Rescheduling is not legalization. The 2024 proposal said that even in Schedule III, manufacturing, distributing, dispensing and possessing marijuana would remain subject to the CSA’s criminal prohibitions.[7]

    How the process unfolded

    DateStep
    6 Oct 2022President Biden asks the Attorney General and HHS to review marijuana’s scheduling[10]
    29 Aug 2023HHS recommends Schedule III[13]
    21 May 2024Justice Department proposes moving marijuana to Schedule III[3]
    29 Aug 2024DEA publishes a hearing notice; the rule draws nearly 43,000 comments[14]
    23 Dec 2025Executive Order 14370 orders the rulemaking finished as fast as federal law allows[15]
    28 Apr 2026Final rule moves FDA-approved and state-licensed medical marijuana to Schedule III; 2024 hearing notice withdrawn and a new hearing called[1][16]
    29 Jun–15 Jul 2026DEA hearing on the broader proposal[4]

    The CSA requires such a change to go through formal rulemaking on the record after an opportunity for a hearing.[3] HHS’s 2023 recommendation found that marijuana has a currently accepted medical use, based partly on more than 30,000 licensed practitioners in 43 US jurisdictions being authorized to recommend it to over 6 million registered patients, and on FDA’s finding of credible scientific support for its use in pain, anorexia linked to certain conditions, and chemotherapy-induced nausea and vomiting.[17] The National Institute on Drug Abuse concurred.[18] For the underlying science, see cannabis and health.

    The December 2025 executive order also asked White House staff to work with Congress on the definition of hemp-derived cannabinoid products, to keep full-spectrum CBD available while restricting risky products.[19]

    What the April 2026 rule did

    The final rule, effective 28 April 2026, placed two categories of marijuana in Schedule III: FDA-approved drug products containing marijuana, and marijuana covered by a state-issued medical marijuana license.[1] The rule cited US obligations under the 1961 Single Convention on Narcotic Drugs, and created an expedited DEA registration process for state medical licensees.[20]

    Its limits matter:

    • Marijuana outside those two categories, including state-legal adult-use (recreational) marijuana, remains in Schedule I.[2]
    • The new registrations do not authorize non-medical use.[2]
    • On taxes, the rule said state medical licensees would no longer face the Section 280E ban on deducting business expenses, which applies only to Schedule I and II trafficking, but that it does not decide anyone’s tax liability.[21]

    The broader proposal: still pending

    On the same day as the final rule, DEA withdrew the 2024 hearing notice, ended those proceedings and called a new hearing on moving all marijuana to Schedule III, citing the executive order.[16][15] DEA’s chief administrative law judge heard testimony between 29 June and 15 July 2026. The law firm Morgan Lewis reports 11 days of testimony from the federal government and seven designated parties.[4]

    As of late September 2026 no final decision had been issued: the parties were awaiting the judge’s recommended decision, after which the DEA administrator makes the final determination. On 29 September 2026 the judge paused the proceedings on a motion by opponents of rescheduling who wanted a new Government Accountability Office report on drug scheduling added to the record.[5] In October the judge refused to reopen the hearing for testimony on the report but admitted it into the record and allowed written briefs until 29 October, with replies due by 5 November. The pause was set to end when that briefing closed. Marijuana Moment reported that the parties filed what were expected to be the final briefs on 5 November, before the judge issues his recommendation to the DEA administrator.[6]

    This page will be updated when DEA issues a recommended or final decision on the broader proposal. Rules for hemp-derived THC and CBD products are covered only briefly here.

    Next in the crash course

    More in Drugs & addiction

    Questions readers ask

    Is marijuana Schedule III now?

    Only partly. A final rule effective 28 April 2026 moved FDA-approved drug products containing marijuana, and marijuana covered by a state medical marijuana license, to Schedule III. Any other marijuana remains in Schedule I.[1][2]

    Does rescheduling make recreational marijuana legal federally?

    No. The 2026 rule's registrations do not authorize non-medical use, and the 2024 proposal said that even in Schedule III, manufacturing, distributing, dispensing and possessing marijuana would remain subject to the Controlled Substances Act's criminal prohibitions.[2][7]

    What is the difference between Schedule I and Schedule III?

    Schedule I drugs have no currently accepted medical use and a high potential for abuse. Schedule III drugs have a lower abuse potential and a currently accepted medical use; examples include ketamine and anabolic steroids.[11][12]

    Why did HHS recommend rescheduling?

    In August 2023 HHS recommended Schedule III after finding marijuana has a currently accepted medical use, citing more than 30,000 practitioners authorized to recommend it to over 6 million patients and FDA's finding of credible scientific support for treating pain, anorexia and chemotherapy nausea. NIDA concurred.[13][17][18]

    What does rescheduling mean for taxes?

    The 2026 rule said state medical licensees would no longer be subject to the Section 280E deduction ban, while stating it does not determine anyone's tax liability.[21]

    What happens next?

    DEA held a hearing on the broader proposal from 29 June to 15 July 2026. As of late September 2026 the next step was a recommended decision from the administrative law judge, followed by a final decision by the DEA administrator. On 29 September the judge paused the proceedings while considering a request from opponents of rescheduling to add a new GAO report on drug scheduling to the record. The judge later admitted the report, refused to reopen the hearing and allowed written briefs instead. Marijuana Moment reported that what were expected to be the final briefs were filed on 5 November 2026, before the judge issues his recommendation.[4][5][6]

    Sources

    · 21 claims from 8 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      A final rule effective 28 April 2026 placed FDA-approved drug products containing marijuana, and marijuana covered by a state medical marijuana license, in Schedule III. confirmedas of 2026-11-07

    2. [2]

      Under the 2026 rule, marijuana other than FDA-approved products or marijuana under a state medical license remains in Schedule I, and the new registrations do not authorize non-medical use. confirmedas of 2026-11-07

    3. [3]

      On 21 May 2024 the Justice Department published a proposed rule to move marijuana from Schedule I to Schedule III, which the CSA requires to go through formal rulemaking on the record after an opportunity for a hearing. confirmedas of 2026-11-07

    4. [4]

      DEA's chief administrative law judge heard testimony between 29 June and 15 July 2026; the law firm Morgan Lewis reports 11 days of testimony from the federal government and seven designated parties. reportedas of 2026-11-07

    5. [5]

      As of late September 2026, the broader proposal to move all marijuana to Schedule III was still pending before DEA's chief administrative law judge, with no final decision; on 29 September 2026 the judge stayed the proceedings on a motion by rescheduling opponents to add a new GAO report on drug scheduling to the record. confirmedas of 2026-11-07

    6. [6]

      In October 2026 the judge declined to reopen the hearing for testimony on the GAO report but admitted the report into the record and allowed briefs on it until 29 October, with replies by 5 November and the stay set to expire when that briefing closed; Marijuana Moment reported that the parties filed what were expected to be the final briefs on 5 November, before the judge issues his recommendation to the DEA administrator. confirmedas of 2026-11-06

    7. [7]

      The 2024 proposal said that even in Schedule III, the manufacture, distribution, dispensing and possession of marijuana would remain subject to the CSA's criminal prohibitions. confirmedas of 2026-11-07

    8. [8]

      The SAMHSA National Helpline, 1-800-662-HELP (4357), and FindTreatment.gov give US referrals to substance use and mental health treatment programs. confirmedas of 2026-11-07

      • Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
    9. [9]

      Under the Controlled Substances Act, drugs and certain chemicals are placed into one of five schedules based on their medical use, potential for abuse and safety or dependence liability. confirmedas of 2026-11-07

    10. [10]

      On 6 October 2022 President Biden asked the Attorney General and the HHS Secretary to start an administrative review of how marijuana is scheduled. confirmedas of 2026-11-07

    11. [11]

      Under the Controlled Substances Act, Schedule I drugs have no currently accepted medical use and a high potential for abuse, while Schedule III drugs have a lower abuse potential than Schedules I and II and a currently accepted medical use. confirmedas of 2026-11-07

    12. [12]

      Drugs in Schedule III include ketamine, anabolic steroids and certain lower-strength codeine products. confirmedas of 2026-11-07

    13. [13]

      In a letter dated 29 August 2023, HHS recommended that DEA place marijuana in Schedule III. confirmedas of 2026-11-07

    14. [14]

      The 2024 proposed rule drew nearly 43,000 public comments, and DEA published a notice of hearing on it on 29 August 2024. confirmedas of 2026-11-07

    15. [15]

      Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research, published in the Federal Register on 23 December 2025, directed the Attorney General to complete the Schedule III rulemaking in the most expeditious manner allowed by federal law. confirmedas of 2026-11-07

    16. [16]

      On 28 April 2026 DEA withdrew the 2024 hearing notice, ended those proceedings, and announced a new hearing on the broader Schedule III proposal to run from 29 June to no later than 15 July 2026. confirmedas of 2026-11-07

    17. [17]

      The HHS recommendation found marijuana has a currently accepted medical use, based partly on more than 30,000 licensed practitioners in 43 US jurisdictions being authorized to recommend it to over 6 million registered patients, and on FDA finding credible scientific support for its use in pain, anorexia linked to certain conditions, and chemotherapy-induced nausea and vomiting. confirmedas of 2026-11-07

    18. [18]

      NIDA concurred with FDA's recommendation that marijuana be moved from Schedule I to Schedule III. confirmedas of 2026-11-07

    19. [19]

      The December 2025 order also directed White House staff to work with Congress on the statutory definition of hemp-derived cannabinoid products so that full-spectrum CBD products could stay available while restricting products that pose serious health risks. confirmedas of 2026-11-07

    20. [20]

      The 2026 final rule cited US obligations under the 1961 Single Convention on Narcotic Drugs and set up an expedited DEA registration process for holders of state medical marijuana licenses. confirmedas of 2026-11-07

    21. [21]

      The 2026 final rule said state medical licensees would no longer be subject to the tax-deduction ban in Section 280E of the Internal Revenue Code, which applies only to trafficking in Schedule I or II substances, while stating that it does not determine anyone's federal tax liability. confirmedas of 2026-11-07

    Revision history (3)
    1. Attributed the September 2026 hearing pause to law-firm summaries.
    2. Added Marijuana Moment as a second source for the hearing pause, credited the 11-day figure to Morgan Lewis, and added the October briefing order and the 5 November final briefs (NORML, Marijuana Moment).
    3. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Jan 7, 2027.

    Cite this page

    "Cannabis rescheduling explained: the DEA process and where it stands." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/cannabis-rescheduling-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.